mRNA

Moderna shares surge after mRNA cancer vaccine clears Phase 3 trial

Moderna shares soared as much as 100% on Wednesday after the company and partner Merck announced that their personalized mRNA cancer vaccine met both primary goals in a pivotal late-stage melanoma trial — the first positive Phase 3 result ever…

Merck, Moderna mRNA cancer vaccine succeeds in Phase 3 trial

Merck and Moderna announced Wednesday that their personalized mRNA cancer vaccine succeeded in a Phase 3 clinical trial, marking the first late-stage positive readout for an individualized neoantigen therapy and for any mRNA-based cancer treatment.

Sanofi sues Pfizer, Moderna over COVID vaccine patents

Sanofi has filed federal lawsuits against both Moderna and Pfizer, alleging their COVID-19 vaccines infringe the French drugmaker's patents covering mRNA technology, according to Reuters.

Moderna’s mRNA cancer prevention vaccine wins UK approval for clinical trial

Moderna and the University of Oxford announced on June 8 that their Phase 1/2 trial of mRNA-4194, an investigational mRNA-based cancer vaccine targeting Lynch syndrome, has received authorization from the UK's Medicines and Healthcare products Regulatory Agency. The trial, called…